A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.

Trial Profile

A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs CNV 2197944 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Peripheral neuropathies
  • Focus Therapeutic Use
  • Sponsors Convergence Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 28 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 08 Jul 2013 Status changed to recruiting according to a Convergence Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top